New Cancer Patients

Today, cardiologists have several therapies to protect the heart but lack the visibility needed to quantify cardio-toxicity or manage the effects of cardio-protective therapy without interrupting cancer treatment.

MyoStrain® enables physicians reliably measure the cardio-toxic effects of chemotherapy in cancer patients. This helps physicians to determine cardio-protective agents and dosage, as well as monitor and manage treatment.¹